CoChat

Pharmacokinetics and Pharmacodynamics of Combined use of Lopinavir/Ritonavir and Rosuvastatin in HIV-Infected Patients

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Background: Lopinavir/ritonavir-containing antiretro-viral therapy can cause hyperlipidaemia. However, most statins are contraindicated due to drug-drug interactions. Rosuvastatin undergoes minimal metabolism by CYP 450 , so no CYP 450 -based interaction with lopinavir/ritonavir is expected. This study explored the lipid-lowering effect of rosuvastatin and assessed the effect of lopinavir/ritonavir on the pharmacokinetics of rosuvastatin and vice versa. Methods: HIV-infected patients on lopinavir/ritonavir (viral load <400 copies/ml) with total cholesterol (TC) >6.2 mmol/l were treated with rosuvastatin for 12 weeks, starting on 10 mg once daily. If fasting target values (TC<5.0 mmol/l, high-density lipoprotein-cholesterol >1.0 mmol/l, low-density lipoprotein-cholesterol [LDL-c] <2.6 mmol/l and triglycerides <2.0 mmol/l) were not reached, rosuvastatin was escalated to 20 mg or 40 mg at week 4 and 8, respectively. Plasma lopinavir/ritonavir trough levels (C min ) were determined at week 0, 4, 8 and 12 and rosuvastatin C min , at week 4, 8 and 12. Results: Twenty-two patients completed the study. Mean reductions in TC and LDL-c from baseline to week 4 (on rosuvastatin 10 mg once a day) were 27.6% and 31.8%, respectively. Lopinavir/ritonavir concentrations were not influenced by rosuvastatin ( P=0.44 and 0.26, repeated-measures analysis). Median (interquartile range) rosuvastatin C min for 10 mg, 20 mg and 40 mg once daily were 0.97 (0.70–1.5), 2.5 (1.3–3.3) and 5.5 (3.3–8.8) ng/ml, respectively. Conclusions: Rosuvastatin appeared to be an effective statin in hyperlipidaemic HIV-infected patients. Lopinavir/ritonavir levels were not affected by rosuvastatin, but rosuvastatin levels unexpectedly appeared to be increased 1.6-fold compared with data from healthy volunteers. Until safety and efficacy have been confirmed in larger studies, the combination of rosuvastatin and lopinavir/ritonavir should be used with caution.

Overview

Integrity signals

Registry

Crossref · 10.1177/135965350701200711

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 33 references

Research works printed but not linked: 3

  1. Crestor, 2006, SmPC Crestor. The Medicines Evaluation Board the Netherlands.
  2. Norvir, Summary of Product Characteristics.
  3. Hoody D., Kiser J., Predhomme J., Flynn D., Gerber J. Drug-drug interaction between lopinavir/ritonavir and rosuvastatin. 14th Conference on Retroviruses and Opportunistic Infections , 25–28 February 2007, Los Angeles, CA, USA. Abstract 564.

Cited by

See all 78

Metadata

Authors
Van Der Lee, M., Sankatsing, R., Schippers, E., Vogel, M., Fätkenheuer, G., Van Der Ven, A., Kroon, F., Rockstroh, J., Wyen, C., Bäumer, A., De Groot, E., Koopmans, P., Stroes, E., Reiss, P., & Burger, D.
Affiliations
  • Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Leiden University Medical Center (NL)
  • University of Bonn (DE)
  • University of Cologne (DE)
  • Nijmegen University Centre for Infectious Diseases, Nijmegen, the Netherlands
  • Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
  • Radboud University Nijmegen (NL)
Venue
Antiviral Therapy
Published
2007-10
Volume
12
Issue
7
Pages
1127-1132
ISSN
  • 1359-6535 (ISSN-L)
  • 2040-2058
OpenAlex
W1480085725
Cited by
78
References
33
Citations by year
2022: 2 · 2021: 5 · 2020: 8 · 2019: 1 · 2018: 1 · 2016: 5 · 2015: 3 · 2014: 3 · 2013: 6 · 2012: 5
FWCI
9.30
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Antiviral Therapy (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Radboud Repository (Radboud University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
Keywords
lopinavir/ritonavir, rosuvastatin, drug-drug interactions, HIV infection, hyperlipidemia, hypolipidemic effect, pharmacokinetics, pharmacodynamics, antiretroviral therapy, statins, cytochrome P450 metabolism, LDL cholesterol, total cholesterol, trough concentration, dose escalation, lipid-lowering therapy
MeSH terms
Rosuvastatin Calcium, Adolescent, Adult, Aged, Drug Therapy, Combination, Fluorobenzenes, Humans, Hypercholesterolemia, Middle Aged, Pilot Projects, Pyrimidines, Pyrimidinones, Sulfonamides, HIV Infections, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Anti-HIV Agents, Ritonavir, Lopinavir

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacokinetics and Pharmacodynamics of Combined use of Lopinavir/Ritonavir and Rosuvastatin in HIV-Infected Patients. https://app.cochat.ai/papers/10.1177/135965350701200711
The paper
Van Der Lee, M., Sankatsing, R., Schippers, E., Vogel, M., Fätkenheuer, G., Van Der Ven, A., Kroon, F., Rockstroh, J., Wyen, C., Bäumer, A., De Groot, E., Koopmans, P., Stroes, E., Reiss, P., & Burger, D. (2007). Pharmacokinetics and Pharmacodynamics of Combined use of Lopinavir/Ritonavir and Rosuvastatin in HIV-Infected Patients. Antiviral Therapy. https://doi.org/10.1177/135965350701200711

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.